Cannabis Science Full Report: What a Phase 2 CBD Autism Trial Found
A 2026 phase 2 open-label cannabidiol autism trial reported early symptom improvement signals with mostly mild adverse events. The study was small and uncontrolled, limiting efficacy conclusions. This trial offers preliminary clinical insights into…
What 26 Studies and 3,598 Patients Reveal About Cannabis and PTSD
This medical cannabis PTSD scoping review examines 26 studies and 3,598 patients. The controlled-trial evidence did not support broad PTSD symptom benefit, with one narrow signal for nabilone and nightmares. The article explains what the review shows,…
CED Cannabis Science Digest: 3 Evidence and Measurement Signals Worth Watching
This digest highlights 3 evidence and measurement signals in cannabis science that help separate clinical proof from preliminary data. It covers systematic reviews, a human HIV biomarker study, and improved cannabinoid measurement methods. These signals…
CED Cannabis Science Digest: 3 Additional Clinical Signals Worth Watching
This digest highlights 3 additional cannabis science signals that sharpen clinical counseling and research endpoints. These signals include Parkinson's nonmotor symptoms, cannabis use disorder endpoints, and cannabinoid hyperemesis syndrome…
Cannabis Use in Early-Onset Psychosis: What the New Meta-Analysis Shows
A 2026 meta-analysis found cannabis use and cannabis use disorder are common in early-onset psychosis and linked to a more complicated clinical picture, but it does not prove causation.
Cannabis for Tourette Tics: What the Meta-Analysis Does and Does Not Prove
A 2026 systematic review and meta-analysis reported reductions in tic severity and premonitory urges with cannabis-based medicines in Tourette syndrome. The signal is promising, but the evidence base is still small, mixed, and not enough to settle…
Cannabinoids for Alzheimer’s Agitation: What a New Meta-Analysis Adds
A new systematic review and meta-analysis found lower agitation and neuropsychiatric symptom scores with cannabinoid-based therapies in Alzheimer’s disease, but the evidence remains limited by small trials, heterogeneous products, short follow-up, and…
Oral CBD and Blood Pressure: What a New Systematic Review Really Shows
A June 2026 systematic review examined whether oral CBD changes blood pressure in adults. The signal is interesting, especially under stress and during sleep, but the trials were small, short, and too heterogeneous to treat CBD as a blood-pressure…
CED Cannabis Science Digest: Immune Activation and CB1-Target Insights
This digest highlights immune activation cannabis research focusing on HIV-linked inflammatory signaling, CB1-target drug design hurdles, and preclinical CBD brain delivery. These three verified cannabis science signals clarify current evidence limits…
Endocannabinoid System & Alcohol Use Disorder: Evidence from Preclinical & Human Studies
Clinical Takeaway The endocannabinoid system plays a measurable role in alcohol use disorder by regulating reward, stress, and emotional processing, making it a viable pharmacological target. A systematic review and meta-analysis of 63 studies found that…